U.S. Emergency Contraceptive Pills Market To Reach $5.1 Billion By 2030

U.S. Emergency Contraceptive Pills Market Growth & Trends

The U.S. emergency contraceptive pills (ECPs) market size is expected to reach USD 5.1 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 5.24% from 2023 to 2030. The rising acceptance of ECPs among women of reproductive age is expected to drive the growth. As more women recognize the importance of emergency contraception and its effectiveness, the market is expected to witness further expansion to meet the increasing demand for accessible and reliable contraceptive options.

The market is anticipated to grow owing to the increasing incidence of unintended pregnancies. These pregnancies can adversely affect women's health, education, career, and family life. According to The National Survey of Family Growth, in 2017, 60.3% of women aged 20 to 44 years at risk of unintended pregnancy used effective contraceptive methods. This data highlights the need for reliable emergency contraception options, leading to the market's growth in response to the increasing demand from women who want to avoid unintended pregnancies.

Key players are implementing various strategies such as partnerships, mergers & acquisitions, expansions, and launching new products to expand their market presence. These strategic initiatives are expected to contribute to the market's growth. For instance, in April 2023, Foundation Consumer Healthcare, a private company manufacturing over-the-counter emergency contraceptive pills and healthcare products, is considering a potential sale worth 4 billion. The company gained prominence in 2017 when it acquired emergency contraception brands like Plan B One-Step from Teva Pharmaceutical Industries, based in Israel. This move contributed to the company's significant recognition in the market.

 Request a free sample copy or view report summary: U.S. Emergency Contraceptive Pills Market Report

U.S. Emergency Contraceptive Pills Market Report Highlights

• Based on type, the progesterone pills segment held the largest market share of over 45% in 2022, owing to the introduction of multiple products from various market players and a high success rate over other options

• Based on distribution channel, the retail store segment held the largest revenue share of over 55% in 2022 during the forecast period. An increasing number of pharmacies in the U.S. that offers a diverse range of products from different market player is expected to drive the market growth

• The online store segment is anticipated to witness the fastest growth during the forecast period. The increasing internet accessibility and growing awareness among women about emergency contraceptives in the U.S. are expected to fuel the segment's growth

• The Southeast region held the largest market share in 2022, primarily due to the increasing prevalence of unplanned pregnancies

U.S. Emergency Contraceptive Pills Market Segmentation

Grand View Research has segmented the U.S. emergency contraceptive pills market based on type, distribution channel, and region:

U.S. Emergency Contraceptive Pills Type Outlook (Revenue, USD Million, 2018 - 2030)

• Combination Pills

• Progesterone Pills

• Ulipristal Acetate

U.S. Emergency Contraceptive Pills Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Retail Store

• Online Store

• Others

U.S. Emergency Contraceptive Pills Regional Outlook (Revenue, USD Million, 2018 - 2030)

• Northeast

• Southeast

• Midwest

• West

• Southwest

List of Key Players in the U.S. Emergency Contraceptive Pills Market

• Afaxys Pharma LLC

• Teva Pharmaceutical Industries Ltd.

• Syzygy Healthcare, LLC

• Gedeon Richter USA, Inc.

• Rapha Pharmaceuticals, Inc.

• Perrigo Company plc

• Foundation Consumer Healthcare LLC

• Wockhardt USA LLC

• Pfizer Inc.

• Bayer plc